GlassScriptPhysician profile
Joseph H Ma
NPI 1689752032
$15,640.01
in general payments reported to CMS, 2019-2025
39 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,347 · 2020: $1,389 · 2021: $2,625 · 2022: $2,344 · 2023: $2,390 · 2024: $2,636 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,749.54 |
| Education | $185.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,886.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,540.59 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $1,409.59 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,351.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $1,268.94 | 2019-2025 | Verquvo, Capvaxive |
| Biotronik INC. | $1,239.70 | 2019-2024 | Acticor 7 Vr-T Dx, Selectra |
| Novartis Pharmaceuticals Corporation | $1,167.16 | 2019-2025 | |
| Amarin Pharma, INC. | $774.21 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $638.89 | 2023-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $547.33 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $515.30 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $399.50 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $390.42 | 2019-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $307.32 | 2021-2025 | |
| Pfizer INC. | $302.18 | 2020-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $247.09 | 2022-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $232.36 | 2019-2024 | Repatha, Krystexxa |
| Abbott Laboratories | $179.17 | 2020-2024 | Jot Dx, Aveir, Mitraclip |
| Arbor Pharmaceuticals, INC. | $148.26 | 2019-2021 | |
| Heartflow, INC. | $138.86 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.51 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $119.43 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $116.48 | 2019-2025 | Watchman Flx, Latitude Communicator Power Supply |
| Gilead Sciences, INC. | $87.90 | 2019 | |
| Exact Sciences Corporation | $73.74 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $60.56 | 2020-2025 | Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $57.39 | 2024 | Evkeeza |
| Scpharmaceuticals INC. | $48.10 | 2024-2025 | |
| Medicomp INC | $36.63 | 2021 | |
| Astellas Pharma US INC | $34.38 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $27.37 | 2024 | Voquezna |
| Sanofi US Services INC. | $26.27 | 2024 | |
| Agepha Pharma Fz LLC | $25.00 | 2025 | Lodoco |
| Ironwood Pharmaceuticals, INC | $23.23 | 2021 | |
| Impulse Dynamics (USA) INC. | $21.62 | 2023 | Optimizer |
| Medtronic, INC. | $20.91 | 2022 | |
| Eisai INC. | $18.24 | 2021 | |
| Horizon Therapeutics Plc | $15.73 | 2020 | |
| Abbvie INC. | $15.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.